Valion Bio, Inc. (VBIO)
2.50
-0.27
(-9.75%)
USD |
NASDAQ |
Sep 08, 16:00
2.45
-0.05
(-2.00%)
Pre-Market: 09:13
Valion Bio Total Liabilities (Quarterly) : 20.59M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 20.59M |
| March 31, 2026 | 19.67M |
| December 31, 2025 | |
| September 30, 2025 | 0.638M |
| June 30, 2025 | 0.821M |
| March 31, 2025 | 0.741M |
| December 31, 2024 | 0.272M |
| September 30, 2024 | 0.56M |
| June 30, 2024 | 0.591M |
| March 31, 2024 | 1.133M |
| December 31, 2023 | 1.674M |
| September 30, 2023 | 1.242M |
| Date | Value |
|---|---|
| June 30, 2023 | 1.435M |
| March 31, 2023 | 1.896M |
| December 31, 2022 | 2.388M |
| September 30, 2022 | 2.436M |
| June 30, 2022 | 2.839M |
| March 31, 2022 | 1.601M |
| December 31, 2021 | 1.764M |
| September 30, 2021 | 7.773M |
| June 30, 2021 | 6.137M |
| March 31, 2021 | 1.764M |
| December 31, 2020 | 2.708M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Outlook Therapeutics, Inc. | 36.58M |
| Agenus, Inc. | 378.54M |
| Amgen, Inc. | 83.95B |
| Anika Therapeutics, Inc. | 46.19M |
| BioCryst Pharmaceuticals, Inc. | 1.012B |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 32.47M |
| Shareholders Equity (Quarterly) | 11.88M |
| Debt to Equity Ratio | 1.465 |
| Current Ratio | 1.110 |
| Net Debt Paydown Yield | -161.3% |